Fundraising Fox
/Companies
Sign in

Hemostemix

Blackfalds · Founded 2014 · 11 employees on LinkedIn · 1 known investors

Find your way into Hemostemix

Each arrow is one introduction. Sign up to fill in the first one.

247 people can intro you to Thomas

Ask Mark Mavroudis to introduce you to Thomas A. Smeenk

You →Mark · together at Xerox Canada →Thomas

10 people can intro you to Kyle

Ask Jamie Chen to introduce you to Kyle Makofka

You →Jamie · together at Ardenton Capital Corporation →Kyle

Sign up to find every way you can get introduced to Hemostemix

  • Your email: who you already know at Hemostemix, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Hemostemix team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Hemostemix is a clinical-stage regenerative medicine company developing ACP-01, an investigational autologous (patient-derived) stem cell therapy for vascular and ischemic conditions such as critical limb ischemia, peripheral arterial disease, ischemic cardiomyopathy, and heart failure. The company runs Phase I and Phase II clinical programs and is publicly traded (TSXV: HEM | OTCQB: HMTXF).

BiotechHealthtechLongevityMedical Devices

Founders & leadership

Hemostemix was founded in 2014 by Roger Bergersen and Thomas A. Smeenk.

RBRoger Bergersen
Roger BergersenFounder (of predecessor TheraVitae Inc.)
TAThomas A. Smeenk
Thomas A. SmeenkPresident & CEO, Co-FounderThomas A. Smeenk is President and CEO of Hemostemix, a publicly traded regenerative medicine company developing ACP-01, an autologous stem cell therapy for ischemic and vascular diseases. He co-founded the company and has led its clinical development and regulatory strategy over multiple decades.
IS
Ina SarelVice President R&D2011–2017Ina Sarel holds a Ph.D. from Boston University and brings research and development and regulatory management experience from biotechnology companies in Israel and the U.S., with expertise in stem cell therapy, cGMP-compliant manufacturing, and regulatory submissions. She serves as VP of Research and Development at Hemostemix.
KMKyle Makofka
Kyle MakofkaCEO2016–2019Kyle Makofka serves as Chief Restructuring Officer at Hemostemix, a publicly traded regenerative medicine company developing stem cell therapies for vascular and cardiac conditions. He brings over 25 years of executive experience in business strategy, operations, and organizational restructuring across private and public companies.
DB
David BermanChief Financial Officer
DF
Dr. Fraser HendersonChief Medical Officer
AJ
Angus JenkinsNamed on SEC filing
DF
Don FriesenNamed on SEC filing
DL
David L. WoodNamed on SEC filing

Investors · 1

Reported raises · per SEC filings

Form D private placements
▶$132.1KofferedSep 2017 · 2 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Angus JenkinsDirector
  • Don FriesenDirector
  • Ina SarelExecutive Officer
  • Kyle MakofkaExecutive Officer
  • David BermanExecutive Officer
  • David L. WoodDirector
Offering amount
$132.1K
First sale
Aug 2017
Incorporated
Corporation, Alberta, Canada, 2014
Federal exemptions
06c
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

American EndovascularOutpatient centers for treatment of peripheral artery disease.
OsmosisOsmosis is a US health education platform of short-form medical videos and learning tools, acquired by Elsevier.

Companies working in the same space as Hemostemix.

In the news

Hemostemix Announces Strategic Manufacturing Partnership with CytoImmune Therapeutics and $1,800,000 in Financing Commitments - Hemostemixhemostemix.com · Aug 2025

Frequently asked questions

What does Hemostemix do?
Hemostemix is a clinical-stage regenerative medicine company developing ACP-01, an investigational autologous (patient-derived) stem cell therapy for vascular and ischemic conditions such as critical limb ischemia, peripheral arterial disease, ischemic cardiomyopathy, and heart failure. The company runs Phase I and Phase II clinical programs and is publicly traded (TSXV: HEM | OTCQB: HMTXF).
Who founded Hemostemix?
Hemostemix was founded by Roger Bergersen, Thomas A. Smeenk in 2014.
Who are Hemostemix's investors?
Hemostemix's investors include BioBrit.
Where is Hemostemix headquartered?
Hemostemix is headquartered in Blackfalds.